Limits...
Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.

Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, McNulty P, Gorzegno G, Freund M, Epoetin Alfa Study Gro - Br. J. Cancer (2002)

Bottom Line: Results of the univariate analysis have been reported previously.The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P<0.05), and confirmed the results of the univariate analysis.These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.

View Article: PubMed Central - PubMed

Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. l.fallowfield@biols.susx.ac.uk

Show MeSH

Related in: MedlinePlus

QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (CLAS scales). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376290&req=5

fig5: QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (CLAS scales). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).

Mentions: QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (FACT-G Total scale and FACT-Fatigue Subscale). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).


Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.

Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, McNulty P, Gorzegno G, Freund M, Epoetin Alfa Study Gro - Br. J. Cancer (2002)

QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (CLAS scales). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376290&req=5

fig5: QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (CLAS scales). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).
Mentions: QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (FACT-G Total scale and FACT-Fatigue Subscale). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).

Bottom Line: Results of the univariate analysis have been reported previously.The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P<0.05), and confirmed the results of the univariate analysis.These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.

View Article: PubMed Central - PubMed

Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. l.fallowfield@biols.susx.ac.uk

Show MeSH
Related in: MedlinePlus